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ABSTRACT
Associated resistance to four to six related and unrelated antimicrobial agents was investigated in
consecutive non-duplicate isolates of Escherichia coli (n = 39 425), Pseudomonas aeruginosa (n = 1070),
Staphylococcus aureus (n = 7489), Streptococcus pneumoniae (n = 1604) and Streptococcus pyogenes
(n = 2531). In all species, high proportions (76.5–88.9%) of isolates were susceptible to all the drugs
investigated. Irrespective of species, isolates resistant to one drug were more likely to be resistant to any
of the other drugs than were susceptible isolates. Thus, trimethoprim resistance in E. coli was 38.4%
among ampicillin-resistant vs. 3.9% among ampicillin-susceptible isolates, and erythromycin resistance
in Strep. pneumoniae was 41% among doxycycline-resistant vs. 1% among doxycycline-susceptible
isolates. In all ﬁve species investigated, there was also signiﬁcant associated resistance among unrelated
drugs, highlighting the fact that resistance development occurs primarily among bacteria already
resistant to one or more antimicrobial agents. For the clinician, pronounced resistance associations mean
that when empirical therapy fails because of resistance, there is a reduced chance of choosing an
alternative successful empirical agent. For the epidemiologist, who uses routine clinical susceptibility
data to describe resistance development, resistance associations mean that if the dataset contains results
for isolates selected on the basis of their susceptibility to another drug, structurally related or not, a bias
of false resistance is introduced.
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INTRODUCTION
Resistance to antimicrobial drugs is increasing
rapidly worldwide in almost all bacterial genera
and to almost all drug classes. The use, misuse
and abuse of antibiotics are held to be responsible
for this development [1,2]. Clonal outbreaks affect
antimicrobial resistance development, as exem-
pliﬁed by Streptococcus pyogenes and macrolide
resistance [3], Neisseria meningitidis and sulphona-
mide resistance [4], Staphylococcus aureus and
fusidic acid resistance [5], and Streptococcus pneu-
moniae and penicillin and trimethoprim–sulpha-
methoxazole resistance [6]. Cross-resistance, i.e.,
resistance to two or more drugs, often mediated
by a single resistance mechanism, is well-docu-
mented and important for resistance to many
classes of antimicrobial agents, e.g., b-lactams,
ﬂuoroquinolones and macrolides [7]. Associated
resistance, i.e., increased resistance to one drug in
the presence of resistance to another unrelated
drug, is only rarely investigated systematically,
although concomitant resistance to many differ-
ent drugs is a well-known phenomenon among
isolates of methicillin-resistant Staph. aureus
and penicillin-resistant Strep. pneumoniae [8]. Only
one previous study has systematically inves-
tigated associated resistance in various patho-
gens to several classes of drugs. Fluit et al. [9]
investigated ten common bacterial pathogens and
described the rates of resistance to a series of
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antimicrobial agents in isolates resistant to the
primary drug. However, this study did not give
or compare resistance rates in bacteria that are
resistant or susceptible to the primary drug.
The objective of the present study was, there-
fore, to determine the degree of associated resis-
tance in ﬁve unrelated bacterial species. To
exclude the possibility that the ﬁndings were
associated randomly with a certain period, iso-
lates of Escherichia coli were studied over a period
of 12 years.
MATERIALS AND METHODS
Study design
The study was performed in the clinical microbiology labora-
tory for the county of Kronoberg, Sweden, which has a
population of 179 000 inhabitants and two small towns, each
with a general hospital. All clinical samples from the area have
been handled by the above-mentioned laboratory since 1985.
Non-duplicate routine quantitative susceptibility test data for
ﬁve pathogens (E. coli, Pseudomonas aeruginosa, Staph. aureus,
Strep. pneumoniae and Strep. pyogenes) were analysed retro-
spectively. With few exceptions (see below), all isolates of the
ﬁve pathogens from hospitalised and community patients
during the periods speciﬁed below were included in the study.
E. coli isolates were from 1993–2004 and isolates of the other
species were from 2001–2004. For E. coli, only urinary tract
isolates were included and a longer period was studied in
order to exclude the possibility that the ﬁndings were
inﬂuenced by a randomly chosen period. E. coli was chosen
for the temporal analysis as: (i) there were enough isolates to
permit the analysis; (ii) it is one of the most common species
isolated in all laboratories; and (iii) the same six antimicrobial
agents were tested throughout the 12-year period. Bacteria
isolated as part of screening programmes for multidrug-
resistant bacteria were not included. All isolates were categor-
ised systematically for susceptibility to four to six deﬁned
antibiotics each. Only antibiotics forming part of the primary
test panel were included, and any isolate without data for all
deﬁned antibiotics was excluded. All data were derived from
the ADBakt database (http://www.autonik.se) used at the
laboratory.
The Swedish Reference Group for Antibiotics (SRGA)
classiﬁcation system (http://www.srga.org) does not have a
susceptible (S) category for E. coli and ampicillin, or for E. coli
and cefadroxil. In these cases, the intermediate (I) category is
considered to represent isolates without any mechanisms of
resistance to the respective drugs, and the I and S categories
were merged. For species–antibiotic combinations where the I
categorisation represented low-level resistance, the results in
susceptibility categories I and resistant (R) were merged.
Antimicrobial susceptibility testing
Breakpoints and susceptibility testing procedures were used as
recommended by the SRGA. All tests were performed on
IsoSensitest agar either without (E. coli, P. aeruginosa,
Staph. aureus) or with (Strep. pneumoniae, Strep. pyogenes)
deﬁbrinated horse blood and b-nicotinamide adenine dinucle-
otide. Reference strains E. coli ATCC 25922, P. aeruginosa
ATCC 27853, Staph. aureus ATCC 29213, Strep. pneumoniae
ATCC 49619 and Strep. pyogenes CCUG 25571 were tested
5 days a week using the same procedure as for the routine
isolates. Routine susceptibility test results were only accepted
if the inhibition zone diameters for the control strains were
within the acceptable performance range.
There were no changes in the SRGA methodology that
affected the studied species and antibiotics during the study
period, except for ﬂuoroquinolones. For the ﬂuoroquinolones,
norﬂoxacin was used in 1993–1998, ciproﬂoxacin in 1999–2000,
and nalidixic acid in 2001–2004. Since nalidixic acid provides a
more sensitive resistance detection system for ﬂuoroquino-
lones, the breakpoints for norﬂoxacin and ciproﬂoxacin were
adapted retrospectively to allow the detection of low-level
ﬂuoroquinolone resistance.
Data presentation
For each of the species, antimicrobial resistance to one drug
was calculated in the presence and absence of resistance to
each of the other drugs investigated. This technique was used
previously in an analysis of all E. coli isolates in the ECOÆSENS
project, performed in 16 European countries and Canada [10];
thus, the principal results of the ECOÆSENS project could be
compared with those of the present study. The ECOÆSENS
study addressed only E. coli isolates and had a geographical,
but not a temporal, aspect.
Statistics
The data were analysed using Microsoft Excel pivot tables.
Statistical analysis calculating the relative risk (p values and
95% CIs) of an isolate being resistant to a second antibiotic
when already resistant to a ﬁrst antibiotic was calculated for all
combinations. Small sample correction was performed in all
the analyses.
RESULTS
In all species, the majority (76.5–88.9%) of isolates
were fully susceptible to all the drugs investigated
(Table 1). For E. coli, this proportion was 78.6% in
1993 and 76.3% in 2004 (p >0.05). The proportion
of isolates resistant to more than one of the drugs
tested was 12.9% for E. coli, 2.7% for P. aeruginosa,
2.9% for Staph. aureus, 3.6% for Strep. pneumoniae,
and 1.5% for Strep. pyogenes. All results concern-
ing associated resistance in these ﬁve species are
presented in Tables 2–6, with the overall resis-
tance rate presented on the bottom line. Associ-
ated resistance, i.e., resistance to one drug in the
presence of resistance to any of the other drugs,
was pronounced in all ﬁve pathogens.
For E. coli (Table 2), six antibiotics were evalu-
able for a total of 39 425 urinary tract isolates.
Trimethoprim resistance was almost ten-fold
316 Clinical Microbiology and Infection, Volume 14 Number 4, April 2008
 2008 The Authors
Journal Compilation  2008 European Society of Clinical Microbiology and Infectious Diseases, CMI, 14, 315–321
higher (38.4% vs. 3.9%) in ampicillin-resistant
than in ampicillin-susceptible isolates of E. coli.
The same pattern was found for all investigated
antimicrobial agents, irrespective of chemical
relatedness, although it was more pronounced
between chemically related drugs such as ampi-
cillin and mecillinam, or ampicillin and cefadroxil
(Table 2). With the exception of ﬂuoroquinolones,
antimicrobial resistance rates changed only mar-
ginally over the 12-year observation period.
Although magnitudes differed, the tendency of
associated resistance was the same in both peri-
ods and for all drugs (Table 2).
For P. aeruginosa, resistance to three related
drugs (piperacillin, ceftazidime and imipenem)
and two unrelated drugs (gentamicin and cipro-
ﬂoxacin) was studied in 1070 consecutive isolates
(Table 3). The same pattern observed for E. coli
was obtained, and all risk ratios were statistically
signiﬁcant, irrespective of whether the drugs were
related or not. As an example, ciproﬂoxacin
resistance was ﬁve- to ten-fold more common,
and gentamicin resistance was ﬁve- to 30-fold
more common, in isolates resistant to any of the
other drugs than in sensitive isolates.
For Staph. aureus, ﬁve drugs could be investi-
gated, two of which (erythromycin and clinda-
mycin) were related. Not surprisingly,
erythromycin resistance was very high (97.2%)
in clindamycin-resistant isolates, and clindamycin
resistance was very high (58.3%) in erythromy-
cin-resistant isolates, but resistance to erythromy-
cin or clindamycin was almost non-existent
among isolates sensitive to the counterpart drug
(Table 4). However, fusidic acid resistance was
also signiﬁcantly higher in isolates resistant to
clindamycin (34.5%) or erythromycin (33.2%)
than in sensitive isolates (13.1% and 12.8%,
respectively).
Table 1. Bacterial species and antimicrobial agents
analysed
Speciesa
No. of
isolates
analysed
Antimicrobial
agents
Isolates without
resistance to
any of the
antimicrobial
agents analysed (%)
Escherichia coli 39 425 FQ, TMP, AMPb,
CFRb, MEC, NIT
76.8
Pseudomonas
aeruginosa
1 070 PIP, CAZ, IPM,
GEN, CIP
85.1
Staphylococcus
aureus
7 489 MET, CLI, ERY,
SXT, FUS
83.4
Streptococcus
pneumoniae
1 604 PEN, CLI, ERY,
DOX, SXT
88.9
Streptocoocus
pyogenes
2 531 PEN, CLI,
ERY, DOX
84.1
FQ, ﬂuoroquinolone; TMP, trimethoprim; AMP, ampicillin; CFR, cefadroxil; MEC,
mecillinam; NIT, nitrofurantoin; PIP, piperacillin; CAZ, ceftazidime; IPM, imipe-
nem; GEN, gentamicin; CIP, ciproﬂoxacin; MET, methicillin; CLI, clindamycin;
ERY, erythromycin; SXT, trimethoprim–sulphamethoxazole; FUS, fusidic acid;
PEN, penicillin; DOX, doxycycline.
aConsecutive isolates between 2000 and 2004, except for E. coli (1993–2004).
bAntibiotics for which the intermediate (I) and susceptible (S) categories were
merged (see Materials and methods).
Table 2. Associated resistance in Escherichia coli isolates (comparison between 1993 and 2004)
Agent and
no. of isolates
susceptible
(S) and
resistant (R)
Antimicrobial resistance (%) in the absence and presence of resistance to another drug and the relative risk (RRa) of resistance in susceptible vs.
resistant organisms
FQ TMP AMP CFR MEC NIT
1993 2004 1993 2004 1993 2004 1993 2004 1993 2004 1993 2004
n
(1993)
n
(2004) % RR % RR % RR % RR % RR % RR % RR % RR % RR % RR % RR % RR
FQ
S 2901 3315 0
NA
0
NA
7.1
4.7
8.6
5.6
16.9
1.3
16.9
3.0
0.7
8.3
0.4
3.7
10.5
1.7
5.8
3.5
0.3
29.9
0.5
8.7
R 25 154 100 100 32.0 48.1 20.0 50.6 4.0 1.3 16.0 20.1 8.0 4.5
TRI
S 2711 3111 0.6
6.1
2.6
8.0
0
NA
0
NA
13.1
5.0
12.1
6.0
0.6
4.2
0.4
3.1
8.0
5.5
4.2
6.3
0.2
10.6
0.5
4.2
R 215 358 3.7 20.7 100 100 65.1 73.2 2.3 1.1 43.7 26.3 2.3 2.2
AMP
S 2431 2830 0.8
1.3
2.7
4.5
3.1
9.1
3.4
12.0
0
NA
0
NA
0.2
19.1
0.1
17.1
1.6
34.7
0.6
55.9
0.3
2.9
0.6
2.1
R 495 639 1.0 12.2 28.3 41.0 100 100 3.4 2.0 54.9 32.6 0.8 1.3
CFR
S 2905 3453 0.8
8.3
4.4
3.4
7.2
3.5
10.3
2.7
16.5
4.9
18.1
4.5
0
NA
0
NA
10.5
2.9
6.3
6.2
0.2
31.1
0.7
4.1
R 21 16 4.8 12.5 23.8 25.0 81.0 81.3 100 100 28.6 37.5 4.8 0.0
MEC
S 2616 3245 0.8
1.8
3.8
3.7
4.6
6.6
8.1
5.2
8.5
10.3
13.3
7.0
0.6
3.5
0.3
8.9
0
NA
0
NA
0.3
5.1
0.6
3.0
R 310 224 1.3 13.8 30.3 42.0 87.7 92.9 1.9 2.7 100 100 1.3 1.8
NIT
S 2915 3444 0.8
27.0
4.3
6.9
7.2
6.6
10.2
3.3
16.8
2.3
18.3
1.8
0.7
28.4
0.5
4.1
10.5
3.7
6.4
2.8
0
NA
0
NA
R 11 25 18.2 28.0 45.5 32.0 36.4 32.0 14.3 0.0 36.4 16.0 100 100
FQ, ﬂuoroquinolone; TMP, trimethoprim; AMP, ampicillin; CFR, cefadroxil; MEC, mecillinam; NIT, nitrofurantoin; NA, not applicable.
aStatistical signiﬁcance for all RRs is shown in bold for p <0.05, and in bold and italics for p <0.001.
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Strep. pneumoniae (Table 5) and Strep. pyogenes
(Table 6) exhibited an identical pattern to
Staph. aureus, except that fusidic acid was not
investigated. All risk ratios were statistically
signiﬁcant, irrespective of whether the drugs
were related. Resistance to other antibiotics was
much higher in penicillin-non-susceptible than in
penicillin-susceptible Strep. pneumoniae. Clinda-
mycin resistance was 8.9% vs. 0.6%, erythromy-
cin resistance was 17.8% vs. 1.5%, doxycycline
resistance was 24.4% vs. 2%, and trimethoprim–
sulphamethoxazole resistance was 80% vs. 6.5%,
respectively.
DISCUSSION
Associated resistance was analysed in ﬁve
unrelated species: E. coli, P. aeruginosa, Staph.
aureus, Strep. pneumoniae and Strep. pyogenes. As
expected, cross-resistance, i.e., resistance to a
drug in the presence of resistance to another
structurally related drug, was common. Surpris-
ingly, associated resistance between structurally
unrelated drugs was also pronounced for almost
all drugs in all ﬁve species. Interestingly, the few
instances in which this was not statistically
signiﬁcant were at the beginning of the period
Table 3. Associated resistance in
Pseudomonas aeruginosa isolates
(2000–2004)
Agent and
no. of isolates
susceptible
(S) and
resistant (R)
Antimicrobial resistance in the absence and presence of resistance to another drug and
the relative risk (RRa) of resistance in susceptible vs. resistant organisms
Piperacillin Ceftazidime Imipenem Gentamicin Ciproﬂoxacin
% RR % RR % RR % RR % RR
Piperacillin
S (n = 1039) 0
NA
0.6
27.9
5.0
3.5
0.3
33.0
7.8
4.7
R (n = 31) 100 16.1 16.1 9.7 35.5
Ceftazidime
S (n = 1059) 2.5
19.1
0
NA
5.1
5.9
0.6
7.1
8.3
4.7
R (n = 11) 45.5 100 27.3 0.0 36.4
Imipenem
S (n = 1013) 2.6
3.7
0.8
7.3
0
NA
0.5
4.8
7.7
3.3
R (n = 57) 8.8 5.3 100 1.8 24.6
Gentamicin
S (n = 1064) 2.6
20.1
1.0
7.1
5.3
4.3
0
NA
8.3
8.3
R (n = 6) 50.0 0.0 16.7 100 66.7
Ciproﬂoxacin
S (n = 978) 2.0
5.9
0.7
6.3
4.4
3.5
0.2
19.0
0
NA
R (n = 92) 12.0 4.3 15.2 4.3 100
Overall resistance
rate (n = 1070)
2.9 1.0 5.3 0.6 8.6
NA, not applicable.
aStatistical signiﬁcance for all RRs is shown in bold for p <0.05, and in bold and italic for p <0.001.
Table 4. Associated resistance in
Staphylococcus aureus isolates (2000–
2004)Agent and
no. of isolates
susceptible (S)
and resistant
(R) to respective
agent
Antimicrobial resistance in the absence and presence of resistance to another drug and
the relative risk (RRa) of resistance in susceptible vs. resistant organisms
Methicillin Clindamycin Erythromycin
Trimetho-
prim–sulpha-
methoxazole Fusidic acid
% RR % RR % RR % RR % RR
Methicillin
S (n = 7480) 0
NA
2.4
6.7
3.9
6.7
0.3
16.1
13.6
0.4
R (n = 9) 100 11.1 22.2 0.0 0.0
Clindamycin
S (n = 7312) 0.1
7.3
0
NA
1.7
57.5
0.3
6.7
13.1
2.6
R (n = 177) 0.6 100 97.2 1.7 34.5
Erythromycin
S (n = 7194) 0.1
8.1
0.1
763.6
0
NA
0.3
2.7
12.8
2.6
R (n = 295) 0.7 58.3 100 0.7 33.2
Trimethoprim–sulphamethoxazole
S (n = 7465) 0.1
16.0
2.3
6.1
3.9
2.6
0
NA
13.6
1.1
R (n = 24) 0.0 12.5 8.3 100 12.5
Fusidic acid
S (n = 6471) 0.1
0.3
1.8
3.4
3.0
3.2
0.3
1.0
0
NA
R (n = 1018) 0.0 6.0 9.6 0.3 100
Overall resistance
rate (n = 7489)
0.1 2.4 3.9 0.3 13.6
NA, not applicable.
aStatistical signiﬁcance for all RRs is shown in bold for p <0.05, and in bold and italic for p <0.001.
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studied, and involved ﬂuoroquinolones, i.e.,
drugs against which resistance was rare in the
beginning and an increasing problem at the end
of the study period.
The ﬁnding of associated resistance underlines
the importance of not using subsets of clinical
susceptibility test data for calculating resistance
rates for epidemiological purposes. If susceptibil-
ity to ciproﬂoxacin is determined only in nalidixic
acid-resistant E. coli, this leads to an obvious bias
that most microbiologists would instantly recog-
nise. However, the data clearly show that the
same tendency exists for unrelated drugs. For
example, if trimethoprim susceptibility is deter-
mined in E. coli isolates resistant to ﬂuoroquino-
lones (or ampicillin or nitrofurantoin), the same
bias ensues. This pattern was seen with all ﬁve
pathogens for all structurally related and almost
all unrelated drugs, and in both older and recent
data for E. coli. Many laboratories extend testing
to include more active drugs or drugs for intra-
venous use ‘if the isolate exhibits resistance to
three or more of the routinely tested ﬁrst-line
antimicrobial agents’ (or according to another
similar algorithm). The present data clearly show
that, although this may be a perfectly sensible and
satisfactory procedure for clinical susceptibility
testing, it obviates the use of the same data for
surveillance and epidemiological purposes. Resis-
tance rates derived from such laboratory practices
become misleading. Although all the E. coli data
concerned isolates from urinary tract infections,
the data for Strep. pneumoniae were from upper
respiratory tract infections, for Staph. aureus from
skin and soft-tissue infections, and for Strep.
pyogenes from throat swabs and soft-tissue infec-
tions. Taken together, there are no data to suggest
that this is not a general phenomenon.
Although several previous reports have
revealed that E. coli isolates resistant to one
antimicrobial agent are likely to be resistant to
other antimicrobial agents [10–15], a systematic
analysis of associated resistance in unrelated
pathogens has not been published previously. In
Table 5. Associated resistance in
Streptococcus pneumoniae isolates
(2000–2004)
Agent and
no. of isolates
susceptible (S)
and resistant (R)
to respective agent
Antimicrobial resistance in the absence and presence of resistance to another drug and
the relative risk (RRa) of resistance in susceptible vs. resistant organisms
Penicillin Clindamycin Erythromycin Doxycycline
Trimetho-
prim–sulpha-
methoxazole
% RR % RR % RR % RR % RR
Penicillin
S (n = 1559) 0
NA
0.6
16.2
1.5
12.4
2.0
12.5
6.5
12.2
R (n = 45) 100 8.9 17.8 24.4 80.0
Clindamycin
S (n = 1591) 2.6
12.8
0
NA
1.1
86.0
1.9
43.0
8.2
7.7
R (n = 13) 30.8 100 100.0 84.6 61.5
Erythromycin
S (n = 1573) 2.4
11.3
0.0
1348.7
0
NA
1.6
34.3
7.9
5.4
R (n = 31) 25.8 41.9 100 54.8 41.9
Doxycycline
S (n = 1562) 2.2
12.3
0.1
169.1
0.9
44.4
0
NA
7.6
6.0
R (n = 42) 26.2 26.2 40.5 100 45.2
Trimethoprim–sulphamethoxazole
S (n = 1466) 0.6
40.7
0.3
16.4
1.2
7.7
1.6
8.8
0
NA
R (n = 138) 26.1 5.8 9.4 13.8 100
Overall resistance
rate (n = 1604)
2.8 0.8 1.9 2.6 8.6
NA, not applicable.
aStatistical signiﬁcance for all RRs is shown in bold for p <0.05, and in bold and italic for p <0.001.
Table 6. Associated resistance in Streptococcus pyogenes
isolates (2000–2004)
Agent and
no. of isolates
susceptible (S)
and resistant (R)
to respective agent
Antimicrobial resistance in the absence and presence of
resistance to another drug and the relative risk (RRa) of
resistance in susceptible vs. resistant organismsb
Clindamycin Erythromycin Doxycycline
% RR % RR % RR
Clindamycin
S (n = 2503) 0
NA
1.4
59.0
14.0
6.4
R (n = 28) 100 85.7 89.3
Erythromycin
S (n = 2471) 0.2
222.4
0
NA
13.8
4.1
R (n = 60) 40.0 100 56.7
Doxycycline
S (n = 2156) 0.1
41.8
1.2
7.5
0
NA
R (n = 375) 6.7 9.1 100
Overall resistance
rate (n = 2531)
1.1 2.4 14.8
NA, not applicable.
aStatistical signiﬁcance for all RRs is shown in bold for p <0.05, and in bold and
italic for p <0.001.
bPenicillin resistance rates are not shown, since all isolates were susceptible to
penicillin.
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2003, the ECOÆSENS project addressed associated
resistance in a more systematic fashion and
revealed that resistance in E. coli to any agent,
not only agents within the same or related classes
of drugs, was associated with a marked increase
in resistance to all other agents tested, with
fosfomycin being a possible exception [10]. This
was true for all 17 countries investigated, and,
together with the present results generated over
longer periods for other species, indicates that this
is a general phenomenon.
In 2005, Kresken et al. [16] reported that four
species of Enterobacteriaceae with resistance to
nalidixic acid frequently exhibited resistance to
non-quinolone agents. Zhanel et al. [11] demon-
strated associations among ampicillin, trimetho-
prim–sulphamethoxazole and ciproﬂoxacin
resistance in 1681 isolates of E. coli from Canada.
Sahm et al. [12] reported similar results from an
analysis in which only 31% of the isolates
included in the study were analysed for resistance
to all antibiotics. Karlowsky et al. [13] conﬁrmed
these results and suggested a connection between
nitrofurantoin and ciproﬂoxacin resistance, and
subsequently concluded from additional data that
ciproﬂoxacin-resistant E. coli isolates were often
multiresistant [14]. In the present study, the
results clearly indicated that associated resistance
is a general phenomenon that is not conﬁned to
particular drug combinations in certain species.
Overall, the present study indicates that, irre-
spective of species, most antimicrobial resistance
development occurs among bacteria that are
already resistant to one or more antimicrobial
agents. The results of the ECOÆSENS study
revealed that c. 70% of E. coli isolates from the
Nordic countries were devoid of resistance to any
of the 12 antimicrobial agents tested, compared
with 76.8% to the six antimicrobial agents tested
in the present study. This is a piece of good news
that is not often recognised. However, the corre-
sponding ﬁgures for Spain and Portugal were
only 30–40% in the ECOÆSENS project [15].
Strategies to counteract resistance often involve
reducing selection pressure by limiting the use
of certain antimicrobial agents or classes of
antimicrobial agents. This strategy pre-supposes
that the ﬁtness cost of resistance will reduce
resistance over time. The present results indicate
that this strategy will often be foiled by
co-selection by almost any drug, whether or not
structurally related. Thus, pronounced associated
resistance would seem to obviate a successful
intervention based on a reduction in use of a
single class of drug. The presence of multidrug
efﬂux pumps and the linkage of resistance genes
in integrons make the dynamics of resistance
development more complex than was thought
originally. Enne et al. [17] reported the same
frequencies of sulphonamide resistance among
E. coli isolates from 1991 and 1999, despite a huge
decrease in prescriptions of sulphonamides in
1995 and thereafter. The failure to observe a
decrease in sulphonamide resistance was ascribed
to associated resistance between sulphonamides
and other antibiotics.
For the clinician, these results mean that should
empirical antimicrobial therapy for a patient fail
because of antimicrobial resistance, the statistical
chance of making an effective second empirical
choice is small. This emphasises the importance of
performing diagnostic culture and susceptibility
testing, not with the aim of indicating empirical
ﬁrst-line therapy, but with the aim of enabling the
clinician to choose the correct antimicrobial agent
should the primary empirical therapy fail.
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